ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Other Events
Item 8.01

On July 2, 2019, the Food and Drug Administration notified ADMA Biologics, Inc. (the “Company”) that the licenses for BIVIGAM^® and Nabi-HB^® have been revoked from Biotest Pharmaceuticals Corporation and transferred and issued to the Company. On July 8, 2019, the Company issued a press release entitled “ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM^® and Nabi-HB^®.” The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

(d) Exhibits

ADMA BIOLOGICS, INC. Exhibit
EX-99.1 2 e618545_ex99-1.htm   Exhibit 99.1       ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®   All Aspects of the Biotest Therapy Business Unit (“BTBU”) Acquisition Are Successfully Completed   RAMSEY,…
To view the full exhibit click here

About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.